NGS-MRD Assessment of Combination Immunotherapies Targeting B-ALL

NCT ID: NCT05262673

Last Updated: 2022-03-08

Basic Information

• Recruitment Status: RECRUITING
• Clinical Phase: PHASE1
• Total Enrollment: 10 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2022-03-01
• Study Completion Date: 2025-12-31

Brief Summary

The purpose of this study is to determine the feasibility, safety, and efficacy of a combination therapy in the treatment of B-cell acute lymphoblastic leukemia (B-ALL) based on multi-antigen-targeted chimeric antigen receptor T cells (CAR-T) followed by engineered immune effector cytotoxic T lymphocytes (CTLs) and immune-modified dendritic cell vaccine (DCvac). This approach is aimed to achieve NGS MRD negative in B-ALL patients, which can identify a very low risk of relapse and define patients with possible long-term remission without further treatment.

Detailed Description

Minimal residual disease (MRD) monitoring is currently performed in B-ALL patients to evaluate treatment response and define risk stratification. Patients with good prognosis have undetectable MRD levels after treatment, while persistent MRD defines high relapse-risk patients. A standardized flow cytometry assay detects MRD reliably in bone marrow or peripheral blood at levels ≥0.01% mononuclear cells. More sensitive MRD assay detecting specific immunoglobulin heavy (IgH) chain rearrangement by next-generation sequencing (NGS) can approach reliably detectable blast level at ≤10-6 cells. Given the high sensitivity, the NGS-MRD approach improves distinction between deeply negative and very low positive cases. Recent studies also demonstrate that NGS-MRD assessment of the bone marrow with undetectable blast cells is a strong predictive factor, indicating patients with possible long-term response after CAR-T cell therapy.

In the past decade, adoptively transferred T cells modified with chimeric antigen receptors (CARs) have demonstrated high effectiveness and changed the treatment paradigm for B-ALL. More than 80% B-ALL patients achieved complete remission due to CAR-T treatment, but some patients with CR still have MRD that ultimately leads to relapse, which indicates the importance for further combination therapy to enhance anti-tumor immunity and to eradicate all malignant cells. Therefore, this protocol includes multi-target CAR-T cell infusions followed by cytotoxic T lymphocyte (CTL)-based immunotherapy, which react with B-ALL tumor antigens, and then followed by injection of immune-modified dendritic cells fused with leukemic cells (DCvac). In addition to the significant success of CAR-T cell therapy, various clinical studies also reported the importance and potential benefits of using engineered tumor-specific T cells in different types of cancer. Moreover, DC-based vaccine as another agent of immunotherapy has proven to prevent or delay relapse in leukemia patients achieving remission. In this study, we propose to combine those strategies to augment anti-tumor immunity in patients and expect undetectable NGS-MRD remission to prevent disease recurrence.

We propose a novel protocol which combines multiple CAR-T cell therapy, engineered immune effector CTLs and DCvac against B-ALL. The aim of this study is to evaluate the feasibility, safety, and efficacy of the NGS-MRD analysis-based combinational immunotherapy.

Conditions

B-Cell Acute Lymphoblastic Leukemia

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

CART/CTL/DCvac cells to treat B-ALL

Group Type: EXPERIMENTAL

Antigen-specific T cells CART/CTL and DCvac

Intervention Type: BIOLOGICAL

Antigen-specific T cells CAR-T/CTL and DCvac cells to treat B-ALL

Interventions

Antigen-specific T cells CART/CTL and DCvac

Antigen-specific T cells CAR-T/CTL and DCvac cells to treat B-ALL

Intervention Type: BIOLOGICAL

Eligibility Criteria

Inclusion Criteria

1. Age older than 6 months.

2. High-burden (≥30% blast cells) B-ALL tumor specimen for clonal IgH identification and CTL/DC vac preparation is required

3. Expression of CD19, CD22, CD20, CD10 or CD123 is determined in malignant cells by flow cytometry or immuno-histochemical staining.

4. Karnofsky performance status (KPS) score is higher than 60 and life expectancy > 3 months.

5. Adequate bone marrow, liver and renal function as assessed by the following laboratory requirements: cardiac ejection fraction ≥ 50%, oxygen saturation ≥ 90%, creatinine ≤ 2.5x upper limit of normal, aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 3x upper limit of normal, total bilirubin ≤ 2.0mg/dL.

6. No cell separation contraindications.

7. Abilities to understand and the willingness to provide written informed consent.

Exclusion Criteria

1. Sever illness or medical condition, which would not permit the patient to be managed according to the protocol, including active uncontrolled infection.

2. Active bacterial, fungal or viral infection not controlled by adequate treatment.

3. Known HIV, hepatitis B virus (HBV) or hepatitis C virus (HCV) infection.

4. Pregnant or nursing women may not participate.

5. History of glucocorticoid for systemic therapy within the week prior to entering the test.

6. Previously treatment with any gene therapy products.

7. Patients, in the opinion of investigators, may not be eligible or not able to comply with the study.

• Minimum Eligible Age: 6 Months
• Maximum Eligible Age: 65 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Shenzhen Geno-Immune Medical Institute

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Locations

Shenzhen Geno-Immune Medical Institute

Shenzhen, Guangdong, China

Site Status: RECRUITING

Countries

China

Central Contacts

Lung-Ji Chang, Ph.D

Role: CONTACT

c@szgimi.org

86-0755-86725195

Facility Contacts

Lung-Ji Chang, Ph.D

Role: primary

c@szgimi.org

86-0755-86725195

Other Identifiers

GIMI-IRB-22001

Identifier Type: -

Identifier Source: org_study_id